Kevin Michael Krause - May 12, 2022 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Strategy Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Kevin Michael Krause
Stock symbol
ANTX
Transactions as of
May 12, 2022
Transactions value $
$0
Form type
4
Date filed
5/16/2022, 09:16 PM
Previous filing
Mar 24, 2022
Next filing
Feb 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Stock Option (right to buy) Award $0 +66K $0.00 66K May 12, 2022 Common Stock 66K $17.28 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from March 25, 2022.